Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTAD

PURCHASE, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers’ Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D.,

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,Casey Mcdonald ,Jort Vijverberg ,Daniel Kontoh Boateng ,Nasdaq ,Cognition Therapeutics Inc ,Company Or Cognition ,Tiberend Strategic Advisors Inc ,National Institutes Of Health ,National Institute Of Aging ,Securities Exchange Commission ,Amsterdam University Medical Center Alzheimer ,Willem De Haan ,Clinical Trials ,Cognition Therapeutics ,National Institute ,National Institutes ,Private Securities Litigation Reform Act ,Strategic Advisors ,Alzheimers Disease ,Sequel ,Tad ,Cognition ,Cognitive Decline ,Reatment Interval ,